Inhibitor of cataract formation

Details Inhibitor of cataract formation Inhibitor of cataract formation

2005-07-05

2005-07-05

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

3,10-dihydroxy-2-naphthacene carboxamide or derivative doai

Reexamination Certificate

active

06914057

ABSTRACT:
Methods of reducing the risk of cataract development in a mammal are provided and include administering to the mammal an effective amount of a tetracycline derivative. A preferred tetracycline derivative administered according to the methods of the present invention is 6α-deoxy 5-hydroxy-4-dedimethylaminotetracycline.

REFERENCES:
patent: 5244673 (1993-09-01), Gejkova et al.
patent: 5474764 (1995-12-01), Patel et al.
patent: 5814655 (1998-09-01), Patel et al.
patent: 5929055 (1999-07-01), Ryan et al.
HCAPLSU, DN 76:30596, (1972), abstract for Smirnov, Makro-Mikrostrukt. Tkanei Norme, Pato.. Eksp. (1969), 34-43.
Patent Abstracts of Japan, vol. 1998, Pub. No. 09315954 (Sep. 12, 1997).
Chemical Abstracts, vol. 93, No. 7, 1980, Columbus, Ohio, US; Abstract No. 60992e, p. 27, XP002294479.
Ryan, M, R. et al. “MMP-mediated Events in Diabetes,” Reprinted from Inhibition of Matrix Metalloproteinases,Annuals of the New York Academy of Sciences878:311-334 (1999).
Butcher, J.M., et al. “Bilateral cataracts and glaucoma induced by long term use of steroid eye drops,”British Medical Journal309(6946):43 (1994).

Affiliated with

Also associated with

Rating

Inhibitor of cataract formation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor of cataract formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of cataract formation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3381187